# SOLO3 (NCT02282020)

> Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02282020
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: AstraZeneca
- Conditions: Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
- Interventions: OLAPARIB; Single agent chemotherapy
- Enrollment: 266
- Primary outcome: Objective Response Rate (ORR)

## Commentary we found

- YouTube: 10
- Podcasts: 10
- X threads: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=solo3-nct02282020

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02282020", "email": "<work email>"}; the inbox owner confirms by the emailed link.